詳細検索

詳細検索

お問い合わせ

2031年までの世界がん診断市場の見通し

2031年までの世界がん診断市場の見通し


Global Cancer Diagnostics Market Outlook, 2031

市場動向 世界のがん診断市場は、悪性腫瘍の検出、特定、および経過観察に利用される技術、ツール、医療処置の包括的なエコシステムを網羅しています。 現代の医療における重要な基盤として機能するこの市場... もっと見る

 

 

出版社
Bonafide Research & Marketing Pvt. Ltd.
ボナファイドリサーチ
出版年月
2026年10月27日
電子版価格
US$4,950
シングルユーザーライセンス
ライセンス・価格情報/注文方法はこちら
納期
2-3営業日以内
ページ数
199
言語
英語

英語原文をAIを使って翻訳しています。


 

サマリー

市場動向

世界のがん診断市場は、悪性腫瘍の検出、特定、および経過観察に利用される技術、ツール、医療処置の包括的なエコシステムを網羅しています。 現代の医療における重要な基盤として機能するこの市場の主な意義は、臨床医に対し、治療可能な早期段階でがんを特定し、精密腫瘍学を通じて個別化された治療戦略を策定するために必要な、正確かつ実用的な知見を提供することにあります。世界的にがんの負担が増大する中、早期発見は患者の生存率を劇的に向上させ、医療費を最適化するため、この分野の重要性はさらに高まっています。 市場の成長は、世界的な高齢化の進展、生活習慣病に関連するがんリスクの高まり、次世代シーケンシング(NGS)、液体生検、AIを活用したデジタル病理学、PETやMRIスキャンなどの高度な画像診断法といった技術的ブレークスルーといった主要な推進要因によって、力強く牽引されています。 さらに、米国がん研究協会(AACR)、 米国臨床腫瘍学会(ASCO)、欧州臨床腫瘍学会(ESMO)、および世界保健機関(WHO)や国際がん研究機関(IARC)といった国際保健機関が、この分野の形成において極めて重要な役割を果たしています。 これらの団体は、最先端の診断研究への資金提供、標準化された臨床ガイドラインの策定、スクリーニングへの広範なアクセス促進、そして新たなバイオマーカーの発見を紹介するための国際会議の開催などを通じて、極めて重要な活動を推進している。 この分野の主要企業は、リスクの高い診断アッセイの研究開発、国境を越えた企業買収、公衆衛生機関との提携による移動式診断ユニットの導入や地域スクリーニングプログラムの展開など、戦略的な活動を継続的に行っています。 最終的には、臨床研究者、規制機関、診断企業間の相乗的な取り組みにより、世界規模でがんと闘うための低侵襲かつ高精度な診断ツールが絶えず進化し続けています。

調査報告書によると、 Bonafide Researchが発表した「2031年までの世界がん診断市場見通し」によると、世界のがん診断市場規模は2031年までに1,689.6億に達すると予想されており、2026年から2031年にかけて年平均成長率(CAGR)は8.45%となる見込みである。 ロシュ・ダイアグノスティックス、サーモフィッシャーサイエンティフィック、イルミナ、アボット・ラボラトリーズ、GEヘルスケア、シーメンス・ヘルスインアーズといった業界をリードする大手企業が、高度な分子検査、画像診断、および組織ベースのソリューションを通じて、この分野を牽引しています。 最近の画期的な進展は、市場の急速な進化を浮き彫りにしている。例えば、ロシュは「BenchMark ULTRA PLUS」を導入して自動診断製品群を拡充し、イルミナは「NovaSeq X」プラットフォームを通じて腫瘍ゲノムプロファイリングを拡大し、アボットは「Alinity」高リスクHPVスクリーニング検査についてFDAの承認を取得した。 さらに、クエスト・ダイアグノスティックスはヘイスタック・オンコロジーを買収し、早期の微小残存病変(MRD)検出の先駆者となった。AIを活用したデジタル病理学の拡大、循環腫瘍DNAを標的とした液体生検アッセイ、および低侵襲な患者層別化を可能にする新規バイオマーカーの発見から、膨大な市場機会が生まれている。 綿密なサプライチェーン分析によると、精密な投入材料に依存する多層的なエコシステムが明らかになった。上流のサプライヤーネットワークは、高品質な生物学的材料、モノクローナル抗体、特殊酵素、マイクロ流体チップ、および画像診断機器用の希少金属を供給している。 中流のメーカーは、これらの構成要素を統合し、厳格なグローバル規制の下で、複雑な次世代シーケンシング(NGS)プラットフォーム、PCR試薬、および自動スライド染色装置を製造している。 下流の流通は、専門的なコールドチェーン物流ネットワークを通じて運営され、病院、学術研究機関、独立診断参照検査機関、および外来診療センターに直接供給を行っています。しかし、このサプライチェーンは、原材料の供給ボトルネック、温度に敏感な輸送の混乱、単一供給源への試薬依存、地域ごとの規制順守状況のばらつきなど、継続的な脆弱性に直面しています。 アジア太平洋地域の新興市場、特にインドと中国は、最も急速に成長している需給の拠点であり、診断へのアクセスを広く普及させるため、地域における製造および流通への投資を加速させている。


市場の動向

市場の推進要因

• 世界的に増大するがんの負担と高齢化社会: 世界的にがんの罹患率が持続的に増加していることが、診断市場の拡大における主な原動力となっています。世界の保健統計によると、世界的な人口の高齢化と、生活習慣に起因するリスク要因(喫煙、不適切な食生活、環境曝露など)が相まって、毎年数百万件のがん新規診断につながっています。 早期発見は、5年生存率の大幅な向上や医療システム全体のコスト削減に直結するため、世界中の公的・民間医療制度は定期的ながん検診プログラムを優先しており、これが診断用消耗品と高度な画像診断インフラの両方に対する持続的な需要を牽引している。
• 精密医療とコンパニオン診断(CDx)の急増: 腫瘍学の分野では、広範囲に作用する化学療法から、標的を絞った生物学的製剤やゲノム治療へと急速にシフトが進んでいます。この変化は、個々の患者における特定の遺伝子変異、バイオマーカーの発現(EGFR、HER2、PD-L1など)、あるいは染色体再編成を特定するために設計された、コンパニオン診断用の特殊な検査法に大きく依存しています。 製薬開発企業や診断企業は、治療効果を確実にするため、標的治療薬と併せてコンパニオン診断キットを共同開発するケースが増えており、これにより分子診断アッセイ・プラットフォームに継続的な収益源がもたらされている。

市場の課題

• 高額な資本コストと複雑な償還のハードル: 次世代シーケンシング(NGS)プラットフォーム、高磁場MRIスキャナー、PET-CT装置などの最先端の診断機器を導入するには、多額の初期投資に加え、継続的なメンテナンス費用や熟練した人材のコストも必要となります。さらに、地域ごとの保険償還制度への対応も大きな障壁となっています。 診断サービス提供者は、新しいマルチ遺伝子パネルや液体生検検査について、保険適用が遅れたり、不統一であったり、不十分であったりする事態に頻繁に直面しており、これが検査室にとって財務上のリスクとなり、コストに敏感な医療環境におけるこれらの検査の普及を妨げている。
• 病理学およびゲノム解析分野における専門人材の不足: 複雑な分子診断結果への依存度が高まるにつれ、有資格人材の世界的な不足が浮き彫りになっています。 マルチオミクスシーケンシングデータや複雑なデジタル病理スライドの解釈に精通した分子生物学者、バイオインフォマティシャン、および専門的な外科病理医は、世界的に不足している。この人材不足は、患者の重要な診断における結果報告までの時間を遅らせ、特に高度な診断サービスの拡充を図ろうとしている二次医療機関や臨床診断施設において、運営上の制約を生み出している。

市場の動向

• 液体生検および微小残存病変(MRD)検査の拡大: 通常の血液検体から循環腫瘍DNA(ctDNA)、無細胞DNA(cfDNA)、および循環腫瘍細胞(CTC)を分析する液体生検技術は、臨床腫瘍学のワークフローに変革をもたらしています。 侵襲的な組織生検を完全に置き換えるのではなく、液体生検は、非侵襲的な早期発見、リアルタイムでの治療法の選択、および治療後の微小残存病変(MRD)のモニタリングにますます採用されており、標準的な画像検査で腫瘍が確認される数ヶ月前に、がんの早期再発を検出することが可能となっています。
• デジタル病理学および画像診断における人工知能(AI)の統合: 人工知能(AI)やディープラーニングアルゴリズムは、診断ワークフローのあらゆる段階に深く組み込まれ、精度とスピードの向上に寄与しています。デジタル病理学の分野では、AIツールが細胞数の自動計数、微小転移の特定、組織病理学スライドのより高精度な分析を行うことで、病理医を支援しています。 同時に、AIを活用した画像診断ソフトウェアは、スキャン取得時間を短縮し、画像解像度を向上させ、CT、MRI、マンモグラフィーの画像において、悪性結節と良性病変の鑑別を放射線科医が容易に行えるよう支援しています。


市場セグメント

試薬や消耗品は、がん診断市場において主要な位置を占めています。これらは、日常的ながん検診、組織分析、分子検査、バイオマーカーの同定に不可欠で、繰り返し使用される資材であるため、診断検査室や医療施設全体で継続的な需要を生み出しているからです。

試薬や消耗品は、がん診断において重要な位置を占めています。というのも、事実上すべての臨床検査ワークフローにおいて、検体の前処理、化学反応、染色、検出、および結果の検証の過程で消費される材料に依存しているからです。数年間は使用し続けることができる診断機器とは異なり、これらの材料は追加の検査を行うたびに補充する必要があります。 代表的な例としては、抗体、アッセイキット、分子プローブ、酵素、緩衝液、染色液、抽出試薬、スライド、検体容器、品質管理用試料などが挙げられる。 従来の組織病理学では、生検や手術によって採取された組織検体を保存、処理、切片化、染色し、顕微鏡下で検査しますが、このプロセスのいくつかの段階において試薬が活用されています。免疫組織化学では、腫瘍組織内のタンパク質を同定するために特定の抗体や検出用試薬が必要であり、これらは病理医ががんを分類し、治療方針の決定に関連するバイオマーカーを評価するのに役立ちます。 ポリメラーゼ連鎖反応(PCR)や次世代シーケンシングを含む分子診断手順においても、同様に、遺伝的変異を検出するために、抽出試薬、プライマー、プローブ、酵素、およびその他のアッセイ固有の成分が必要となります。これらの要件は初期診断にとどまりません。なぜなら、疾患が進行したり、治療後に再発したり、その後の治療選択に影響を与える特徴が現れたりした場合、患者は追加の検査を受ける可能性があるからです。 また、検査室では、分析性能を確認し、信頼性の高い結果を維持するために、適切なコントロールおよび検証済みの材料を使用する必要があります。精密腫瘍学の拡大に伴い、特定の変異、タンパク質の発現、およびその他の臨床的に意義のある腫瘍の特徴を特定するために設計された特殊な試薬の重要性がさらに高まっています。 また、診断プラットフォームには互換性のある消耗品が必要となる場合が多く、検査室の業務を中断なく行うためには、信頼性の高い製品供給が不可欠です。検査手法がより専門化されるにつれ、検査室では、さまざまな検体種類、分析手法、およびがんバイオマーカーに適した、より幅広い種類の試薬を必要としています。

体外診断(IVD)検査は、がん診断技術分野を牽引しており、血液、組織、その他の生体試料に対する検査室での分析が、がんの検出、腫瘍の分類、バイオマーカーの評価、そしてますます個別化が進む治療方針の決定を支えていることから、同分野で最も急成長しているセグメントであると言える。

体外診断は、症状や身体検査だけでは確実に把握できない生物学的特徴を検査技師が調査することを可能にするため、がん治療において中心的な役割を果たしています。疑われるがんの種類や臨床上の課題に応じて、検査には腫瘍組織、血液、骨髄、その他の生体検体が用いられることがあり、選択される検査法は疾患の種類や必要な情報によって決定されます。 多くの癌の診断において、組織病理学的検査は依然として不可欠ですが、検査室で行われる免疫測定法、分子生物学的手法、細胞遺伝学的手法、およびその他の分析手順は、腫瘍の生物学的特性に関する追加情報を提供します。 例えば、ポリメラーゼ連鎖反応(PCR)により特定の遺伝子変異を同定できる一方、次世代シーケンシングでは複数の遺伝子を解析し、治療法の選択に影響を与える可能性のある変化を検出することができる。免疫組織化学検査は、腫瘍細胞が特定のタンパク質を発現しているかどうかを明らかにすることができ、乳がんにおけるHER2検査がその一例である。これは、臨床医がHER2を標的とした治療が適切かどうかを判断するのに役立つ。 分子検査は、標的療法に関連する特定の変異を同定し、特定の肺がんやその他の悪性腫瘍に対する治療法の選択を支援することもできる。こうした応用により、IVDは初期診断の段階だけでなく、臨床医が治療を選択する前に腫瘍の分類を精緻化したり、バイオマーカーを調査したりする必要がある場合にも有用である。 この技術の重要性は、標準化された検査手順、検証済みのアッセイ、適切な品質管理、および臨床的に解釈可能な結果の必要性によってさらに強調されています。その成長加速の可能性は、プレシジョン・オンコロジーの拡大、分子検査の普及、マルチ遺伝子パネルの利用増加、および少量または複雑な検体における臨床的に関連性のある変化を検出できるアッセイの開発と関連しています。 循環腫瘍DNA(ctDNA)解析を含む一部の血液ベースのアプローチも、特定された臨床用途に向けて研究・採用が進められているが、その適性はがんの種類や使用目的によって異なる。

乳がんは、世界中の女性において最も多く診断されるがんの一つであり、治療プロセス全体を通じて広範なスクリーニング、確定検査、腫瘍の特性評価、およびバイオマーカーの評価が必要とされるため、がん診断分野において最大の応用分野を占めています。

乳がんは、その大きな臨床的負担が、確立されたスクリーニングプログラム、専門的な画像診断サービス、病理検査のワークフロー、および治療に関連する臨床検査の開発を促進してきたため、がん診断において重要な位置を占めています。 国際がん研究機関(IARC)によると、2020年に乳がんは世界中で最も多く診断されたがんであり、2024年においても女性において最も多く診断されたがんの地位を維持していた。ただし、男女を合わせて考えると、肺がんが第1位であった。この違いは、疾患カテゴリーごとに診断用途を検討する際、なぜ乳がんが特に重要視されるのかを説明する一因となっている。 マンモグラフィは、しこりが触知される前に疑わしい変化を検出できるため、主要なスクリーニング法となっています。これにより、適応があれば患者はさらなる検査を受けることが可能になります。 スクリーニング結果に異常が見られたからといって、自動的に悪性腫瘍と断定されるわけではありません。その所見を詳しく調べるために、診断用マンモグラフィー、超音波検査、場合によっては磁気共鳴画像法(MRI)が用いられることがあります。必要に応じて、乳房生検を行い、組織を採取して顕微鏡検査を行い、診断を確定します。 その後、病理医が腫瘍の組織型、悪性度、関連するバイオマーカープロファイルなど、腫瘍の特性を判定します。エストロゲン受容体、プロゲステロン受容体、およびHER2の検査結果は、内分泌療法やHER2標的治療の選択に影響を与える可能性があるため、特に重要です。特定の患者や臨床状況によっては、追加の分子検査が適切となる場合もあります。 したがって、診断の目的は、腫瘍の疑いがある病変を検出するだけでなく、その生物学的挙動を明らかにし、必要に応じてリンパ節転移の有無を評価し、治療計画に必要な情報を提供することにも及びます。また、患者に新たな疑わしい病変が認められた場合、再発の可能性がある場合、あるいは腫瘍の特徴の再評価が必要な場合にも、検査が再度行われることがあります。 乳がんの治療には、放射線科、病理科、外科、腫瘍科など、複数の専門分野が連携して関与しており、それにより、同一の患者の診療過程において複数の診断の接点が生まれます。

病院は、がん診断分野において最大のエンドユーザー層を構成しています。これは、病院には診断検査室、画像診断部門、生検サービス、専門医、治療施設が一堂に集まっており、患者が単一の医療機関内で連携のとれたがん評価を受けられるためです。

病院はがん診断において重要な役割を担っています。なぜなら、悪性腫瘍が疑われる場合の検査は、単一の検査室での検査にとどまらず、多くの場合、複数の臨床部門が連携して行われるからです。患者は、当初、症状を訴えたり、スクリーニング検査で異常所見が認められたり、あるいは別の疾患の検査中に偶然発見されたりすることがあります。 病院の医療チームは、疑われる腫瘍の種類や患者の臨床的ニーズに応じて、放射線科、臨床検査科、病理科、外科、腫瘍科などを通じて、その後の評価を調整することができます。 画像検査は、疑わしい病変の位置を特定し、その範囲を評価するのに役立ちます。一方、生検は、適応がある場合に病理学的確認のための組織や細胞材料を提供します。病院の病理検査室では、検体の処理、組織形態の検査、および腫瘍の特性を明らかにするための免疫組織化学や分子検査などの追加検査を行います。これらの所見は、臨床医が異なるがんの種類を区別し、治療開始前にさらなる検査が必要かどうかを判断するのに役立ちます。 病院では、特に画像所見、組織学的所見、検査結果、および患者の病歴情報を組み合わせて診断を下す必要がある場合など、多職種による検討を要する複雑な症例にも対応しています。一部の患者では、治療中の再評価、再発の疑いに関する調査、あるいは新たな症状の評価が必要となるため、初期の確定診断後も病院の診断責任は継続します。 がん手術では、検査用の追加の組織検体が得られ、高度な治療プログラムでは、特定の治療法の適格性を判断するために専門的なバイオマーカー検査が必要となる場合がある。大規模な病院や専門のがんセンターは、独自の検査室や高度な診断機器を保有している場合がある一方、他の病院では、特定の専門知識や技術が院内にない場合、選定された検体を外部の検査機関に送付することがある。 いずれの体制においても、たとえすべての検査が院内で行われるわけではない場合でも、病院ががん診断サービスの主要な利用者および購入者としての役割を強化している。また、病院の検査室には、訓練を受けた病理医や検査技師、品質管理システム、検体追跡手順、そして試薬や消耗品の確実な供給が必要とされる。 診断結果を治療計画に統合する能力を持つため、病院は包括的ながん医療において重要な拠点となっている。独立した診断検査機関や専門の外来診療センターも相当数の検査を行っているが、病院はしばしば、複雑な病状、侵襲的な診断処置、複数の併存疾患、および緊急の治療を必要とする患者を受け入れている。


地域別インサイト

北米は、確立された医療インフラ、充実した検査体制、先進的な診断技術の積極的な導入、そして十分に整備されたがん検診・治療システムが、診断検査の広範な利用を支えていることから、世界のがん診断市場をリードしている。

北米ががん診断分野で占める地位は、先進的な医療インフラ、確立された病理検査サービス、専門的ながん医療へのアクセス、そして検査結果を臨床判断に組み込む体制が相まって支えられている。 特に米国は、その医療システムに大学附属医療センター、総合がんセンター、病院検査室、独立系診断機関、および専門的な分子検査施設が含まれているため、極めて重要な役割を果たしている。 米国国立がん研究所(NCI)は、診断科学、臨床研究、および研究成果の医療現場への応用を強化するプログラムを通じて、がん研究を支援している。さらに、NCIの「サーベイランス・疫学・最終結果(SEER)プログラム」は、がんの発生率、生存率、死亡率に関する情報を収集・公表しており、この疾患に対する集団レベルの理解を深めるとともに、研究や公衆衛生計画の策定に情報を提供している。 がん検診および早期発見サービスも診断活動に寄与しており、臨床ガイドラインや個々のリスク要因に基づき、乳がん、子宮頸がん、大腸がん、その他のがんに対して確立されたアプローチが用いられている。
•アメリカ合衆国 The United States occupies a leading position in North American cancer diagnostics because its healthcare infrastructure supports a wide range of diagnostic activities, from routine screening and conventional pathology to specialized molecular investigations. The country also has established screening recommendations for several cancers, including breast and colorectal cancer, while cervical cancer screening uses established methods such as human papillomavirus testing and Pap testing.


Key Devlopments

•August 2026: Precipio is strengthening its cancer diagnostics business through expanding commercialization of its proprietary diagnostic products and a growing customer pipeline. Its pathology infrastructure gives Precipio direct access to patient specimens and clinical workflows, supporting faster development and validation of new diagnostic solutions.
• August 2026: Abbott is applying user-experience design to cancer diagnostic sample-collection packaging to make testing simpler and reduce friction for healthcare professionals and patients. Its cancer diagnostic sample-collection kits, including Cologuard, are being designed around the distinct needs of phlebotomists, pathologists, and at-home screening users.
• August 2026: New Mexico Cancer Center became the first facility in New Mexico to offer Cerianna (FES) PET imaging for eligible patients with recurrent or metastatic ER-positive breast cancer. The imaging uses an estrogen-receptor-targeting radiotracer to identify ER-positive disease throughout the body.
• July 2026: Ibex Medical Analytics received CE-IVDR certification for Ibex Breast ER, PR and Ki67, completing regulatory certification across its breast cancer diagnostic portfolio. The AI-powered solution automates biomarker quantification, improving scoring consistency while reducing manual pathology workload.
• June 2026: Veracyte launched its Prosigna Breast Risk of Recurrence test to help identify early-stage breast cancer patients who could safely avoid chemotherapy. The genomic test analyzed the activity of 50 genes to assess recurrence risk and guide personalized treatment decisions.
• May 2026: Roche Diagnostics Asia Pacific collaborated with AstraZeneca to accelerate a sustainable ecosystem for advanced pathology in breast and lung cancer. This partnership aims to enhance diagnostic capabilities and support better patient outcomes in breast and lung cancer treatment through advanced pathology solutions.
• May 2026: The FDA approved Myriad Genetics' companion diagnostic for ovarian cancer, advancing precision medicine in cancer treatment. This approval enables clinicians to identify patients who may benefit from specific ovarian cancer therapies through genetic testing. The companion diagnostic supports targeted treatment decisions for ovarian cancer patients.
• March 2026: Rhythm Biosciences highlighted the strategic importance of NATA accreditation for commercializing ColoSTAT, its blood-based colorectal cancer diagnostic test. The accreditation confirms compliance with ISO 15189:2022 requirements for clinical testing and supports delivery of the test through accredited laboratory services.
• October 2025: DermaSensor secured $16 million to scale AI-powered skin cancer detection in primary care settings. The funding supports the deployment of the company's AI-driven diagnostic technology that enables primary care providers to detect skin cancer earlier and more accurately. This advancement brings sophisticated skin cancer detection capabilities to routine clinical practice.
• September 2025: F. Hoffmann-La Roche’s VENTANA HER2 (4B5) test received CE-IVDR approval to support the assessment of HER2-ultralow status, enabling identification of metastatic breast cancer patients eligible for treatment with ENHERTU.
• July 2025: Bern-based medtech company Compremium launched a human clinical study for its non-invasive thyroid cancer diagnostic device that measures tissue compressibility to better distinguish between benign and malignant nodules. The 18-month trial at Bern University Hospital targets patients with Bethesda IV nodules to help reduce unnecessary thyroid surgeries.
• July 2025: Fred Hutch Cancer Center launched the Vanguard Study, the first trial under the Cancer Screening Research Network (CSRN), to assess the effectiveness of multi-cancer detection (MCD) blood tests in adults aged 45-75.


Considered in this report
• Historic Year: 2020
• Base year: 2025
• Estimated year: 2026
• Forecast year: 2031

Aspects covered in this report
• Cancer Diagnostics Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Product Type
• Consumables and reagents
• Instruments

By Technology
• IVD testing
• Anatomic pathology
• Diagnostic imaging
• Biopsy

By Application
• Breast Cancer
• Colorectal Cancer
• Lung Cancer
• Prostate Cancer
• Others

***Please Note: It will take 48 hours (2 Business days) for delivery of the report upon order confirmation.



お問い合わせ

お問合せ種類/内容 *

補足が有ればご記入ください
貴社名*
ご担当者名 * 姓 名
メールアドレス *

ページTOPに戻る


目次

目次

1. エグゼクティブ・サマリー
2. 市場の動向
2.1. 市場の推進要因と機会
2.2. 市場の制約要因と課題
2.3. 市場のトレンド
2.4. サプライチェーン分析
2.5. 政策・規制の枠組み
2.6. 業界専門家の見解
3. 調査方法
3.1. 二次調査
3.2. 一次データ収集
3.3. 市場形成および検証
3.4. レポート作成、品質チェックおよび納品
4. 市場構造
4.1. 市場に関する考慮事項
4.2. 仮定
4.3. 制限事項
4.4. 略語
4.5. 出典
4.6. 定義
5. 経済・人口統計の概要
6. 世界の癌診断市場の展望
6.1. 金額ベースの市場規模
6.2. 地域別市場シェア
6.3. 地域別市場規模および予測
6.4. 製品タイプ別市場規模および予測
6.4.1. 消耗品・試薬別市場規模および予測
6.4.2. 機器別市場規模および予測
6.5. 技術別市場規模および予測
6.6. 用途別市場規模および予測
6.7. エンドユーザー別市場規模および予測
7. 北米がん診断市場の展望
7.1. 金額ベースの市場規模
7.2. 国別市場シェア
7.3. 製品タイプ別市場規模および予測
7.4. 技術別市場規模および予測
7.5. 用途別市場規模および予測
7.6. エンドユーザー別市場規模および予測
7.7. 米国のがん診断市場の展望
7.7.1. 金額ベースの市場規模
7.7.2. 製品タイプ別市場規模および予測
7.7.3. 技術別市場規模および予測
7.7.4. 用途別市場規模および予測
7.8. カナダのがん診断市場の展望
7.8.1. 金額ベースの市場規模
7.8.2. 製品タイプ別市場規模および予測
7.8.3. 技術別市場規模および予測
7.8.4. 用途別市場規模および予測
7.9. メキシコのがん診断市場の展望
7.9.1. 金額ベースの市場規模
7.9.2. 製品タイプ別市場規模および予測
7.9.3. 技術別市場規模および予測
7.9.4. 用途別市場規模および予測
8. 欧州のがん診断市場の展望
8.1. 金額ベースの市場規模
8.2. 国別の市場シェア
8.3. 製品タイプ別の市場規模と予測
8.4. 技術別の市場規模と予測
8.5. 用途別の市場規模と予測
8.6. エンドユーザー別市場規模および予測
8.7. ドイツのがん診断市場の展望
8.7.1. 金額ベースの市場規模
8.7.2. 製品タイプ別市場規模および予測
8.7.3. 技術別市場規模および予測
8.7.4. 用途別市場規模および予測
8.8. 英国(UK)のがん診断市場の展望
8.8.1. 金額ベースの市場規模
8.8.2. 製品タイプ別市場規模および予測
8.8.3. 技術別市場規模および予測
8.8.4. 用途別市場規模および予測
8.9. フランスのがん診断市場の展望
8.9.1. 金額ベースの市場規模
8.9.2. 製品タイプ別市場規模および予測
8.9.3. 技術別市場規模および予測
8.9.4. 用途別市場規模および予測
8.10. イタリアのがん診断市場の展望
8.10.1. 金額ベースの市場規模
8.10.2. 製品タイプ別の市場規模と予測
8.10.3. 技術別の市場規模と予測
8.10.4. 用途別の市場規模と予測
8.11. スペインのがん診断市場の展望
8.11.1. 市場規模(金額ベース)
8.11.2. 製品タイプ別の市場規模と予測
8.11.3. 技術別の市場規模と予測
8.11.4. 用途別の市場規模と予測
8.12. ロシアのがん診断市場の展望
8.12.1. 金額ベースの市場規模
8.12.2. 製品タイプ別の市場規模および予測
8.12.3. 技術別の市場規模および予測
8.12.4. 用途別の市場規模および予測
9. アジア太平洋地域のがん診断市場の展望
9.1. 金額ベースの市場規模
9.2. 国別市場シェア
9.3. 製品タイプ別の市場規模と予測
9.4. 技術別の市場規模と予測
9.5. 用途別の市場規模と予測
9.6. エンドユーザー別の市場規模と予測
9.7. 中国のがん診断市場の展望
9.7.1. 金額ベースの市場規模
9.7.2. 製品タイプ別の市場規模と予測
9.7.3. 技術別の市場規模と予測
9.7.4.用途別の市場規模と予測
9.8.日本のがん診断市場の見通し
9.8.1. 金額ベースの市場規模
9.8.2. 製品タイプ別の市場規模と予測
9.8.3. 技術別の市場規模と予測
9.8.4. 用途別の市場規模と予測
9.9. インドのがん診断市場の見通し
9.9.1. 金額ベースの市場規模
9.9.2. 製品タイプ別の市場規模と予測
9.9.3. 技術別の市場規模と予測
9.9.4. 用途別の市場規模と予測
9.10. オーストラリアのがん診断市場の見通し
9.10.1. 金額ベースの市場規模
9.10.2. 製品タイプ別の市場規模と予測
9.10.3. 技術別の市場規模と予測
9.10.4. 用途別の市場規模と予測
9.11. 韓国のがん診断市場の展望
9.11.1. 金額ベースの市場規模
9.11.2. 製品タイプ別の市場規模と予測
9.11.3. 技術別の市場規模と予測
9.11.4. 用途別の市場規模と予測
10. 南米のがん診断市場の展望
10.1. 金額ベースの市場規模
10.2. 国別市場シェア
10.3. 製品タイプ別市場規模および予測
10.4. 技術別市場規模および予測
10.5. 用途別市場規模および予測
10.6. エンドユーザー別市場規模および予測
10.7. ブラジルのがん診断市場の展望
10.7.1. 金額ベースの市場規模
10.7.2. 製品タイプ別の市場規模と予測
10.7.3. 技術別の市場規模と予測
10.7.4. 用途別の市場規模と予測
10.8. アルゼンチンのがん診断市場の展望
10.8.1. 金額ベースの市場規模
10.8.2. 製品タイプ別の市場規模および予測
10.8.3. 技術別の市場規模および予測
10.8.4. 用途別の市場規模および予測
10.9. コロンビアのがん診断市場の展望
10.9.1. 金額ベースの市場規模
10.9.2. 製品タイプ別の市場規模と予測
10.9.3. 技術別の市場規模と予測
10.9.4. 用途別の市場規模と予測
11. 中東・アフリカのがん診断市場の展望
11.1. 金額ベースの市場規模
11.2. 国別市場シェア
11.3. 製品タイプ別の市場規模と予測
11.4. 技術別の市場規模と予測
11.5. 用途別市場規模および予測
11.6. エンドユーザー別市場規模および予測
11.7. アラブ首長国連邦(UAE)のがん診断市場の展望
11.7.1. 金額ベースの市場規模
11.7.2. 製品タイプ別の市場規模および予測
11.7.3. 技術別市場規模および予測
11.7.4. 用途別市場規模および予測
11.8. サウジアラビアのがん診断市場の展望
11.8.1. 金額ベースの市場規模
11.8.2. 製品タイプ別市場規模および予測
11.8.3. 技術別市場規模および予測
11.8.4. 用途別市場規模および予測
11.9. 南アフリカのがん診断市場の展望
11.9.1. 金額ベースの市場規模
11.9.2. 製品タイプ別の市場規模および予測
11.9.3. 技術別市場規模および予測
11.9.4. 用途別市場規模および予測
12. 競争環境
12.1. 競争ダッシュボード
12.2. 主要企業が採用する事業戦略
12.3. 主要企業の市場シェアに関する洞察と分析(2025年)
12.4. 主要企業の市場ポジショニング・マトリックス
12.5. ポーターの5つの力
12.6. 企業概要
12.6.1. サーモフィッシャーサイエンティフィック社
12.6.1.1. 企業概要
12.6.1.2. 会社概要
12.6.1.3. 財務ハイライト
12.6.1.4. 地域別動向
12.6.1.5. 事業セグメントおよび業績
12.6.1.6. 製品ポートフォリオ
12.6.1.7. 主要経営陣
12.6.1.8. 戦略的動きと動向
12.6.2. アボット・ラボラトリーズ
12.6.3. アジレント・テクノロジーズ社
12.6.4. ロシュ・ダイアグノスティックス
12.6.5. ダナハー・コーポレーション
12.6.6. シーメンス・ヘルスインアーズAG
12.6.7. キアゲンN.V.
12.6.8. ベクトン・ディキンソン・アンド・カンパニー(BD)
12.6.9. イルミナ社
12.6.10. ホロジック社
12.6.11. バイオメリュー(bioMérieux SA)
12.6.12. ファウンデーション・メディシン(Foundation Medicine, Inc.)
12.6.13. シスメックス株式会社(Sysmex Corporation)
12.6.14. ネオジェノミクス・ラボラトリーズ(NeoGenomics Laboratories, Inc.)
12.6.15. マイリアド・ジェネティクス(Myriad Genetics, Inc.)
12.6.16. エクザクト・サイエンシズ・コーポレーション
12.6.17. ガーダント・ヘルス社
12.6.18. グレイル社
12.6.19. ナテラ社
12.6.20. テンパスAI社
13. 戦略的提言
14. 付録
14.1. よくある質問(FAQ)
14.2. 注記
15. 免責事項

ページTOPに戻る



図表リスト

List of Figures

Figure 1: Global Cancer Diagnostics Market Size (USD Billion) By Region, 2025 & 2031F
Figure 2: Market attractiveness Index, By Region 2031F
Figure 3: Market attractiveness Index, By Segment 2031F
Figure 4: Global Cancer Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 5: Global Cancer Diagnostics Market Share By Region (2025)
Figure 6: North America Cancer Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 7: North America Cancer Diagnostics Market Share By Country (2025)
Figure 8: US Cancer Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 9: Canada Cancer Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 10: Mexico Cancer Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 11: Europe Cancer Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 12: Europe Cancer Diagnostics Market Share By Country (2025)
Figure 13: Germany Cancer Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 14: United Kingdom (UK) Cancer Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 15: France Cancer Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 16: Italy Cancer Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 17: Spain Cancer Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 18: Russia Cancer Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 19: Asia-Pacific Cancer Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 20: Asia-Pacific Cancer Diagnostics Market Share By Country (2025)
Figure 21: China Cancer Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 22: Japan Cancer Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 23: India Cancer Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 24: Australia Cancer Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 25: South Korea Cancer Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 26: South America Cancer Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 27: South America Cancer Diagnostics Market Share By Country (2025)
Figure 28: Brazil Cancer Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 29: Argentina Cancer Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 30: Colombia Cancer Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 31: Middle East & Africa Cancer Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 32: Middle East & Africa Cancer Diagnostics Market Share By Country (2025)
Figure 33: United Arab Emirates (UAE) Cancer Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 34: Saudi Arabia Cancer Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 35: South Africa Cancer Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 36: Porter's Five Forces of Global Cancer Diagnostics Market


List of Tables

Table 1: Global Cancer Diagnostics Market Snapshot, By Segmentation (2025 & 2031F) (in USD Billion)
Table 2: Influencing Factors for Cancer Diagnostics Market, 2025
Table 3: Top 10 Counties Economic Snapshot 2024
Table 4: Economic Snapshot of Other Prominent Countries 2022
Table 5: Average Exchange Rates for Converting Foreign Currencies into U.S. Dollars
Table 6: Global Cancer Diagnostics Market Size and Forecast, By Geography (2020 to 2031F) (In USD Billion)
Table 7: Global Cancer Diagnostics Market Size and Forecast, By Product Type (2020 to 2031F) (In USD Billion)
Table 8: Global Cancer Diagnostics Market Size and Forecast, By Consumables and reagents (2020 to 2031F) (In USD Billion)
Table 9: Global Cancer Diagnostics Market Size and Forecast, By Instruments (2020 to 2031F) (In USD Billion)
Table 10: Global Cancer Diagnostics Market Size and Forecast, By Technology (2020 to 2031F) (In USD Billion)
Table 11: Global Cancer Diagnostics Market Size and Forecast, By Application (2020 to 2031F) (In USD Billion)
Table 12: Global Cancer Diagnostics Market Size and Forecast, By End User (2020 to 2031F) (In USD Billion)
Table 13: North America Cancer Diagnostics Market Size and Forecast, By Product Type (2020 to 2031F) (In USD Billion)
Table 14: North America Cancer Diagnostics Market Size and Forecast, By Technology (2020 to 2031F) (In USD Billion)
Table 15: North America Cancer Diagnostics Market Size and Forecast, By Application (2020 to 2031F) (In USD Billion)
Table 16: North America Cancer Diagnostics Market Size and Forecast, By End User (2020 to 2031F) (In USD Billion)
Table 17: United States Cancer Diagnostics Market Size and Forecast By Product Type (2020 to 2031F) (In USD Billion)
Table 18: United States Cancer Diagnostics Market Size and Forecast By Technology (2020 to 2031F) (In USD Billion)
Table 19: United States Cancer Diagnostics Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)
Table 20: Canada Cancer Diagnostics Market Size and Forecast By Product Type (2020 to 2031F) (In USD Billion)
Table 21: Canada Cancer Diagnostics Market Size and Forecast By Technology (2020 to 2031F) (In USD Billion)
Table 22: Canada Cancer Diagnostics Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)
Table 23: Mexico Cancer Diagnostics Market Size and Forecast By Product Type (2020 to 2031F) (In USD Billion)
Table 24: Mexico Cancer Diagnostics Market Size and Forecast By Technology (2020 to 2031F) (In USD Billion)
Table 25: Mexico Cancer Diagnostics Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)
Table 26: Europe Cancer Diagnostics Market Size and Forecast, By Product Type (2020 to 2031F) (In USD Billion)
Table 27: Europe Cancer Diagnostics Market Size and Forecast, By Technology (2020 to 2031F) (In USD Billion)
Table 28: Europe Cancer Diagnostics Market Size and Forecast, By Application (2020 to 2031F) (In USD Billion)
Table 29: Europe Cancer Diagnostics Market Size and Forecast, By End User (2020 to 2031F) (In USD Billion)
Table 30: Germany Cancer Diagnostics Market Size and Forecast By Product Type (2020 to 2031F) (In USD Billion)
Table 31: Germany Cancer Diagnostics Market Size and Forecast By Technology (2020 to 2031F) (In USD Billion)
Table 32: Germany Cancer Diagnostics Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)
Table 33: United Kingdom (UK) Cancer Diagnostics Market Size and Forecast By Product Type (2020 to 2031F) (In USD Billion)
Table 34: United Kingdom (UK) Cancer Diagnostics Market Size and Forecast By Technology (2020 to 2031F) (In USD Billion)
Table 35: United Kingdom (UK) Cancer Diagnostics Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)
Table 36: France Cancer Diagnostics Market Size and Forecast By Product Type (2020 to 2031F) (In USD Billion)
Table 37: France Cancer Diagnostics Market Size and Forecast By Technology (2020 to 2031F) (In USD Billion)
Table 38: France Cancer Diagnostics Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)
Table 39: Italy Cancer Diagnostics Market Size and Forecast By Product Type (2020 to 2031F) (In USD Billion)
Table 40: Italy Cancer Diagnostics Market Size and Forecast By Technology (2020 to 2031F) (In USD Billion)
Table 41: Italy Cancer Diagnostics Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)
Table 42: Spain Cancer Diagnostics Market Size and Forecast By Product Type (2020 to 2031F) (In USD Billion)
Table 43: Spain Cancer Diagnostics Market Size and Forecast By Technology (2020 to 2031F) (In USD Billion)
Table 44: Spain Cancer Diagnostics Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)
Table 45: Russia Cancer Diagnostics Market Size and Forecast By Product Type (2020 to 2031F) (In USD Billion)
Table 46: Russia Cancer Diagnostics Market Size and Forecast By Technology (2020 to 2031F) (In USD Billion)
Table 47: Russia Cancer Diagnostics Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)
Table 48: Asia-Pacific Cancer Diagnostics Market Size and Forecast, By Product Type (2020 to 2031F) (In USD Billion)
Table 49: Asia-Pacific Cancer Diagnostics Market Size and Forecast, By Technology (2020 to 2031F) (In USD Billion)
Table 50: Asia-Pacific Cancer Diagnostics Market Size and Forecast, By Application (2020 to 2031F) (In USD Billion)
Table 51: Asia-Pacific Cancer Diagnostics Market Size and Forecast, By End User (2020 to 2031F) (In USD Billion)
Table 52: China Cancer Diagnostics Market Size and Forecast By Product Type (2020 to 2031F) (In USD Billion)
Table 53: China Cancer Diagnostics Market Size and Forecast By Technology (2020 to 2031F) (In USD Billion)
Table 54: China Cancer Diagnostics Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)
Table 55: Japan Cancer Diagnostics Market Size and Forecast By Product Type (2020 to 2031F) (In USD Billion)
Table 56: Japan Cancer Diagnostics Market Size and Forecast By Technology (2020 to 2031F) (In USD Billion)
Table 57: Japan Cancer Diagnostics Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)
Table 58: India Cancer Diagnostics Market Size and Forecast By Product Type (2020 to 2031F) (In USD Billion)
Table 59: India Cancer Diagnostics Market Size and Forecast By Technology (2020 to 2031F) (In USD Billion)
Table 60: India Cancer Diagnostics Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)
Table 61: Australia Cancer Diagnostics Market Size and Forecast By Product Type (2020 to 2031F) (In USD Billion)
Table 62: Australia Cancer Diagnostics Market Size and Forecast By Technology (2020 to 2031F) (In USD Billion)
Table 63: Australia Cancer Diagnostics Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)
Table 64: South Korea Cancer Diagnostics Market Size and Forecast By Product Type (2020 to 2031F) (In USD Billion)
Table 65: South Korea Cancer Diagnostics Market Size and Forecast By Technology (2020 to 2031F) (In USD Billion)
Table 66: South Korea Cancer Diagnostics Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)
Table 67: South America Cancer Diagnostics Market Size and Forecast, By Product Type (2020 to 2031F) (In USD Billion)
Table 68: South America Cancer Diagnostics Market Size and Forecast, By Technology (2020 to 2031F) (In USD Billion)
Table 69: South America Cancer Diagnostics Market Size and Forecast, By Application (2020 to 2031F) (In USD Billion)
Table 70: South America Cancer Diagnostics Market Size and Forecast, By End User (2020 to 2031F) (In USD Billion)
Table 71: Brazil Cancer Diagnostics Market Size and Forecast By Product Type (2020 to 2031F) (In USD Billion)
Table 72: Brazil Cancer Diagnostics Market Size and Forecast By Technology (2020 to 2031F) (In USD Billion)
Table 73: Brazil Cancer Diagnostics Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)
Table 74: Argentina Cancer Diagnostics Market Size and Forecast By Product Type (2020 to 2031F) (In USD Billion)
Table 75: Argentina Cancer Diagnostics Market Size and Forecast By Technology (2020 to 2031F) (In USD Billion)
Table 76: Argentina Cancer Diagnostics Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)
Table 77: Colombia Cancer Diagnostics Market Size and Forecast By Product Type (2020 to 2031F) (In USD Billion)
Table 78: Colombia Cancer Diagnostics Market Size and Forecast By Technology (2020 to 2031F) (In USD Billion)
Table 79: Colombia Cancer Diagnostics Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)
Table 80: Middle East & Africa Cancer Diagnostics Market Size and Forecast, By Product Type (2020 to 2031F) (In USD Billion)
Table 81: Middle East & Africa Cancer Diagnostics Market Size and Forecast, By Technology (2020 to 2031F) (In USD Billion)
Table 82: Middle East & Africa Cancer Diagnostics Market Size and Forecast, By Application (2020 to 2031F) (In USD Billion)
Table 83: Middle East & Africa Cancer Diagnostics Market Size and Forecast, By End User (2020 to 2031F) (In USD Billion)
Table 84: United Arab Emirates (UAE) Cancer Diagnostics Market Size and Forecast By Product Type (2020 to 2031F) (In USD Billion)
Table 85: United Arab Emirates (UAE) Cancer Diagnostics Market Size and Forecast By Technology (2020 to 2031F) (In USD Billion)
Table 86: United Arab Emirates (UAE) Cancer Diagnostics Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)
Table 87: Saudi Arabia Cancer Diagnostics Market Size and Forecast By Product Type (2020 to 2031F) (In USD Billion)
Table 88: Saudi Arabia Cancer Diagnostics Market Size and Forecast By Technology (2020 to 2031F) (In USD Billion)
Table 89: Saudi Arabia Cancer Diagnostics Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)
Table 90: South Africa Cancer Diagnostics Market Size and Forecast By Product Type (2020 to 2031F) (In USD Billion)
Table 91: South Africa Cancer Diagnostics Market Size and Forecast By Technology (2020 to 2031F) (In USD Billion)
Table 92: South Africa Cancer Diagnostics Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)
Table 93: Competitive Dashboard of top 5 players, 2025
Table 94: Key Players Market Share Insights and Analysis for Cancer Diagnostics Market 2025

 

ページTOPに戻る


 

Summary

Market Insights

The global cancer diagnostics market encompasses the complete ecosystem of technologies, tools, and medical procedures utilized to detect, identify, and monitor malignant tumors. Functioning as a critical cornerstone of modern healthcare, its primary relevance lies in providing clinicians with precise actionable insights needed to identify cancer at early, treatable stages and tailor personalized therapeutic strategies through precision oncology. The importance of this sector is magnified by the escalating worldwide burden of cancer, where early detection dramatically improves patient survival rates and optimizes healthcare expenditure. Market growth is aggressively propelled by key drivers such as an expanding global aging population, rising lifestyle-related cancer risks, and technological breakthroughs like Next-Generation Sequencing (NGS), liquid biopsies, AI-driven digital pathology, and advanced imaging modalities like PET and MRI scans. Additionally, prominent global healthcare and scientific associations including the American Association for Cancer Research (AACR), the American Society of Clinical Oncology (ASCO), the European Society for Medical Oncology (ESMO), and global health organizations like the World Health Organization (WHO) and the International Agency for Research on Cancer (IARC) play a pivotal role in shaping this landscape. These bodies drive vital activities by funding cutting-edge diagnostic research, establishing standardized clinical guidelines, advocating for widespread screening access, and hosting global congresses to showcase emerging biomarker discoveries. Commercial leaders in this space continuously engage in strategic activities, including high-stakes diagnostic assay R&D, cross-border corporate acquisitions, and partnerships with public health entities to deploy mobile diagnostic units and community screening programs. Ultimately, the synergistic activities between clinical researchers, governing associations, and diagnostic companies ensure the continuous evolution of minimally invasive, highly accurate diagnostic tools to combat cancer globally.

According to the research report, “Global Cancer Diagnostics Market Outlook, 2031” published by Bonafide Research, the Global Cancer Diagnostics Market is expected to cross 168.96 Billion market size by 2031, with 8.45% CAGR by 2026-31. Leading industry giants such as Roche Diagnostics, Thermo Fisher Scientific, Illumina, Abbott Laboratories, GE HealthCare, and Siemens Healthineers drive this sector through advanced molecular testing, imaging, and tissue-based solutions. Recent breakthroughs highlight rapid commercial evolution; for instance, Roche expanded its automated diagnostic portfolio with BenchMark ULTRA PLUS, Illumina expanded oncology genomic profiling via its NovaSeq X platforms, and Abbott secured FDA approval for its Alinity high-risk HPV screening assay. Furthermore, Quest Diagnostics acquired Haystack Oncology to pioneer early minimal residual disease (MRD) detection. Immense market opportunities stem from expanding AI-driven digital pathology, liquid biopsy assays targeting circulating tumor DNA, and novel biomarker discoveries that enable minimally invasive patient stratification. A rigorous supply chain analysis reveals a multi-tiered ecosystem reliant on precision inputs. Upstream supplier networks provide high-grade biological materials, monoclonal antibodies, specialized enzymes, microfluidic chips, and rare metals for diagnostic imaging instruments. Midstream manufacturers integrate these components to produce complex next-generation sequencing (NGS) platforms, PCR reagents, and automated slide stainers under stringent global regulatory oversight. Downstream distribution operates through specialized cold-chain logistics networks, directly supplying hospitals, academic research institutes, independent diagnostic reference laboratories, and outpatient care centers. However, the supply chain faces ongoing vulnerabilities, including raw material supply bottlenecks, temperature-sensitive shipment disruptions, single-source reagent dependencies, and regional regulatory compliance variations. Emerging markets in the Asia-Pacific region, particularly India and China, represent the fastest-growing supply and demand hubs, accelerating regional manufacturing and distribution investments to democratize diagnostic access.


Market Dynamics

Market Drivers

• Escalating global cancer burden and aging demographics: The persistent increase in global cancer incidence serves as the primary driver for diagnostic market expansion. According to global health estimates, the combination of an aging global population and lifestyle-induced risk factors (such as smoking, poor diet, and environmental exposures) has led to millions of new cancer diagnoses annually. Because early-stage detection directly correlates with significantly higher 5-year survival rates and reduced systemic healthcare costs, public and private healthcare systems worldwide are prioritizing routine cancer screening programs, driving sustained demand for both diagnostic consumables and advanced imaging infrastructure.
• Surge in precision medicine and companion diagnostics (CDx): The oncology landscape is rapidly shifting away from broad-spectrum chemotherapy toward targeted biologic and genomic therapies. This evolution relies heavily on companion diagnostics specialized assays designed to identify specific genetic mutations, biomarker expressions (e.g., EGFR, HER2, PD-L1), or chromosomal rearrangements in individual patients. Pharmaceutical developers and diagnostic companies are increasingly co-developing companion diagnostic kits alongside targeted drugs to ensure therapeutic efficacy, generating recurring revenue streams for molecular diagnostic assay platforms.

Market Challenges

• High capital costs and complex reimbursement hurdles: Deploying cutting-edge diagnostic equipment such as Next-Generation Sequencing (NGS) platforms, high-field MRI scanners, and PET-CT instruments requires substantial upfront capital expenditure alongside ongoing maintenance and skilled labor costs. Furthermore, navigating regional reimbursement frameworks presents a major bottleneck. Diagnostic providers frequently encounter delayed, inconsistent, or insufficient insurance coverage for novel multi-gene panels and liquid biopsy tests, creating financial risk for labs and limiting widespread adoption in cost-sensitive healthcare environments.
• Shortage of specialized pathology and genomic talent: The growing reliance on complex molecular diagnostic outputs has highlighted a global deficit in qualified workforce personnel. Molecular biologists, bioinformaticians, and specialized surgical pathologists trained to interpret multi-omic sequencing data and intricate digital pathology slides are in short supply worldwide. This workforce bottleneck delays turnaround times for critical patient diagnostics and creates operational constraints, particularly for secondary hospitals and clinical diagnostic facilities attempting to expand their advanced diagnostic offerings.

Market Trends

• Expansion of liquid biopsies and minimal residual disease (MRD) testing: Liquid biopsy technologies which analyze circulating tumor DNA (ctDNA), cell-free DNA (cfDNA), and circulating tumor cells (CTCs) from standard blood samples are transforming clinical oncology workflows. Rather than replacing invasive tissue biopsies entirely, liquid biopsies are increasingly adopted for non-invasive early detection, real-time therapy selection, and monitoring post-treatment Minimal Residual Disease (MRD) to detect early cancer recurrence months before visible tumors appear on standard radiological scans.
• Integration of artificial intelligence (AI) in digital pathology and imaging: Artificial intelligence and deep learning algorithms are becoming deeply embedded across diagnostic workflows to enhance accuracy and speed. In digital pathology, AI tools assist pathologists by automating cell counting, identifying micro-metastases, and analyzing histopathology slides with greater precision. Simultaneously, AI-enhanced diagnostic imaging software reduces scan acquisition times, improves image resolution, and aids radiologists in distinguishing malignant nodules from benign lesions on CT, MRI, and mammography scans.


Market Segments

Reagents and consumables dominate the cancer diagnostics market because they are indispensable, repeatedly used materials required for routine cancer detection, tissue analysis, molecular testing, and biomarker identification, creating continuous demand across diagnostic laboratories and healthcare facilities.

Reagents and consumables occupy a leading position in cancer diagnostics because virtually every laboratory testing workflow depends on materials that are consumed during sample preparation, chemical reactions, staining, detection, and result validation. Unlike diagnostic instruments, which can remain operational for several years, these materials must be replenished whenever additional tests are performed. Common examples include antibodies, assay kits, molecular probes, enzymes, buffers, staining solutions, extraction reagents, slides, specimen containers, and quality-control materials. In conventional histopathology, tissue specimens obtained through biopsies or surgery are preserved, processed, sectioned, stained, and examined under a microscope, with reagents supporting several stages of this process. Immunohistochemistry requires specific antibodies and detection chemicals to identify proteins within tumor tissue, helping pathologists classify cancers and assess biomarkers relevant to treatment decisions. Molecular diagnostic procedures, including polymerase chain reaction and next-generation sequencing, similarly require extraction chemicals, primers, probes, enzymes, and other assay-specific components to detect genetic alterations. These requirements extend beyond the initial diagnosis because patients may undergo additional testing when the disease progresses, returns after treatment, or develops characteristics that influence subsequent therapeutic choices. Laboratories must also use appropriate controls and validated materials to check analytical performance and maintain reliable results. The expansion of precision oncology has further increased the importance of specialised reagents designed to identify particular mutations, protein expressions, and other clinically meaningful tumor characteristics. Diagnostic platforms also frequently require compatible consumables, making reliable product supply essential for uninterrupted laboratory operations. As testing methods become more specialised, laboratories need a broader selection of reagents suited to different specimen types, analytical techniques, and cancer biomarkers.

In vitro diagnostics (IVD) testing leads the cancer diagnostics technology segment and can be identified as its fastest-growing segment because laboratory-based analysis of blood, tissue, and other biological specimens supports cancer detection, tumor classification, biomarker assessment, and increasingly personalised treatment decisions.

In vitro diagnostics plays a central role in cancer care because it enables laboratory professionals to investigate biological characteristics that cannot be reliably established through symptoms or physical examination alone. Depending on the suspected cancer and the clinical question, testing may involve tumor tissue, blood, bone marrow, or other biological specimens, with the selected method determined by the disease and the information required. Histopathological examination remains essential for many cancer diagnoses, while laboratory-based immunoassays, molecular techniques, cytogenetic methods, and other analytical procedures provide additional information about tumor biology. For example, polymerase chain reaction can identify selected genetic alterations, while next-generation sequencing can examine multiple genes to detect changes that may influence treatment selection. Immunohistochemistry can establish whether tumor cells express specific proteins, as demonstrated by HER2 testing in breast cancer, which helps clinicians determine whether HER2-directed treatment may be appropriate. Molecular testing can also identify certain alterations relevant to targeted therapies and support the selection of treatments for particular lung cancers and other malignancies. These applications make IVD useful not only at the point of initial diagnosis but also when clinicians need to refine a tumor classification or investigate biomarkers before choosing a treatment. The technology's importance is reinforced by the need for standardized laboratory procedures, validated assays, appropriate quality controls, and clinically interpretable results. Its potential for faster growth is associated with the expansion of precision oncology, wider availability of molecular testing, increasing use of multigene panels, and the development of assays that can detect clinically relevant changes in small or complex specimens. Some blood-based approaches, including circulating tumor DNA analysis, are also being investigated and adopted for selected clinical applications, although their suitability varies by cancer type and intended use.

Breast cancer represents the largest application segment in cancer diagnostics because it is one of the most frequently diagnosed cancers among women worldwide and requires extensive screening, confirmatory testing, tumor characterization, and biomarker assessment throughout the care pathway.

Breast cancer occupies a prominent position in cancer diagnostics because its substantial clinical burden has encouraged the development of established screening programmes, specialised imaging services, pathology workflows, and treatment-linked laboratory testing. According to the International Agency for Research on Cancer, breast cancer was the most commonly diagnosed cancer worldwide in 2020 and remained the most frequently diagnosed cancer among women in 2024, although lung cancer ranked first when both sexes were considered together. This distinction helps explain why breast cancer is particularly important when diagnostic applications are examined by individual disease category. Mammography is a central screening method because it can reveal suspicious changes before a lump becomes noticeable, allowing patients to undergo further assessment when indicated. An abnormal screening result does not automatically establish malignancy; diagnostic mammography, ultrasound, and sometimes magnetic resonance imaging may be used to investigate the finding. When necessary, a breast biopsy provides tissue for microscopic examination and confirmation of the diagnosis. Pathologists then determine the tumor’s characteristics, including its histological type, grade, and relevant biomarker profile. Tests for estrogen receptors, progesterone receptors, and HER2 are particularly important because their results can influence the selection of endocrine therapy or HER2-targeted treatment. Additional molecular investigations may be appropriate for particular patients and clinical circumstances. Diagnostic demand therefore extends beyond detecting a suspected tumor to establishing its biological behavior, evaluating lymph-node involvement where relevant, and providing information needed for treatment planning. Testing can also recur when a patient develops a new suspicious lesion, experiences a possible recurrence, or requires reassessment of tumor characteristics. Breast cancer care involves several coordinated specialties, including radiology, pathology, surgery, and oncology, which creates multiple diagnostic touchpoints within the same patient journey.

Hospitals constitute the largest end-user segment in cancer diagnostics because they bring together diagnostic laboratories, imaging departments, biopsy services, specialist clinicians, and treatment facilities, enabling patients to receive coordinated cancer evaluation within a single healthcare institution.

Hospitals hold an important position in cancer diagnostics because investigating a suspected malignancy frequently involves several clinical departments rather than one isolated laboratory test. A patient may initially present with symptoms, an abnormal screening result, or an incidental finding during an examination for another condition. Hospital teams can coordinate the subsequent assessment through radiology, laboratory medicine, pathology, surgery, and oncology, depending on the suspected tumor and the patient's clinical needs. Imaging examinations help locate suspicious lesions and assess their extent, while biopsy procedures provide tissue or cellular material for pathological confirmation when indicated. Hospital pathology laboratories process specimens, examine tissue morphology, and conduct additional investigations such as immunohistochemistry or molecular testing to establish tumor characteristics. These findings help clinicians distinguish between different cancer types and determine whether further testing is needed before treatment begins. Hospitals also manage complex cases requiring multidisciplinary review, particularly when diagnosis depends on combining imaging observations, histological findings, laboratory results, and information about the patient's medical history. Their diagnostic responsibilities continue after initial confirmation because some patients require reassessment during treatment, investigation of suspected recurrence, or evaluation of new symptoms. Cancer surgery generates additional tissue specimens for examination, and advanced treatment programmes may require specialised biomarker tests to determine eligibility for particular therapies. Large hospitals and specialised cancer centres may maintain their own laboratories and sophisticated diagnostic equipment, whereas other hospitals send selected specimens to external reference laboratories when particular expertise or technology is unavailable locally. Both arrangements reinforce hospitals' role as major users and purchasers of cancer diagnostic services, even when not every test is performed on their premises. Hospital laboratories also require trained pathologists, laboratory scientists, quality-management systems, specimen-tracking procedures, and reliable supplies of reagents and consumables. Their ability to integrate diagnostic findings with treatment planning makes them important settings for comprehensive cancer care. Although independent diagnostic laboratories and specialist outpatient centres also perform substantial testing, hospitals frequently handle patients with complicated conditions, invasive diagnostic procedures, multiple comorbidities, and immediate treatment needs.


Regional Insights

North America leads the global cancer diagnostics market because its established healthcare infrastructure, extensive laboratory capabilities, strong adoption of advanced diagnostic technologies, and well-developed cancer screening and treatment systems support widespread use of diagnostic testing.

North America's position in cancer diagnostics is supported by the combination of advanced medical infrastructure, established pathology services, access to specialised oncology care, and the integration of laboratory findings into clinical decision-making. The United States is a particularly important contributor because its healthcare system includes academic medical centres, comprehensive cancer centres, hospital laboratories, independent diagnostic providers, and specialised molecular testing facilities. The National Cancer Institute supports cancer research through programmes that strengthen diagnostic science, clinical investigation, and the translation of research findings into medical practice. In addition, the National Cancer Institute's Surveillance, Epidemiology, and End Results programme collects and publishes cancer incidence, survival, and mortality information, supporting population-level understanding of the disease and informing research and public health planning. Cancer screening and early-detection services also contribute to diagnostic activity, with established approaches for breast, cervical, colorectal, and other cancers used according to clinical guidelines and individual risk factors.
• USA: The United States occupies a leading position in North American cancer diagnostics because its healthcare infrastructure supports a wide range of diagnostic activities, from routine screening and conventional pathology to specialized molecular investigations. The country also has established screening recommendations for several cancers, including breast and colorectal cancer, while cervical cancer screening uses established methods such as human papillomavirus testing and Pap testing.


Key Devlopments

• August 2026: Precipio is strengthening its cancer diagnostics business through expanding commercialization of its proprietary diagnostic products and a growing customer pipeline. Its pathology infrastructure gives Precipio direct access to patient specimens and clinical workflows, supporting faster development and validation of new diagnostic solutions.
• August 2026: Abbott is applying user-experience design to cancer diagnostic sample-collection packaging to make testing simpler and reduce friction for healthcare professionals and patients. Its cancer diagnostic sample-collection kits, including Cologuard, are being designed around the distinct needs of phlebotomists, pathologists, and at-home screening users.
• August 2026: New Mexico Cancer Center became the first facility in New Mexico to offer Cerianna (FES) PET imaging for eligible patients with recurrent or metastatic ER-positive breast cancer. The imaging uses an estrogen-receptor-targeting radiotracer to identify ER-positive disease throughout the body.
• July 2026: Ibex Medical Analytics received CE-IVDR certification for Ibex Breast ER, PR and Ki67, completing regulatory certification across its breast cancer diagnostic portfolio. The AI-powered solution automates biomarker quantification, improving scoring consistency while reducing manual pathology workload.
• June 2026: Veracyte launched its Prosigna Breast Risk of Recurrence test to help identify early-stage breast cancer patients who could safely avoid chemotherapy. The genomic test analyzed the activity of 50 genes to assess recurrence risk and guide personalized treatment decisions.
• May 2026: Roche Diagnostics Asia Pacific collaborated with AstraZeneca to accelerate a sustainable ecosystem for advanced pathology in breast and lung cancer. This partnership aims to enhance diagnostic capabilities and support better patient outcomes in breast and lung cancer treatment through advanced pathology solutions.
• May 2026: The FDA approved Myriad Genetics' companion diagnostic for ovarian cancer, advancing precision medicine in cancer treatment. This approval enables clinicians to identify patients who may benefit from specific ovarian cancer therapies through genetic testing. The companion diagnostic supports targeted treatment decisions for ovarian cancer patients.
• March 2026: Rhythm Biosciences highlighted the strategic importance of NATA accreditation for commercializing ColoSTAT, its blood-based colorectal cancer diagnostic test. The accreditation confirms compliance with ISO 15189:2022 requirements for clinical testing and supports delivery of the test through accredited laboratory services.
• October 2025: DermaSensor secured $16 million to scale AI-powered skin cancer detection in primary care settings. The funding supports the deployment of the company's AI-driven diagnostic technology that enables primary care providers to detect skin cancer earlier and more accurately. This advancement brings sophisticated skin cancer detection capabilities to routine clinical practice.
• September 2025: F. Hoffmann-La Roche’s VENTANA HER2 (4B5) test received CE-IVDR approval to support the assessment of HER2-ultralow status, enabling identification of metastatic breast cancer patients eligible for treatment with ENHERTU.
• July 2025: Bern-based medtech company Compremium launched a human clinical study for its non-invasive thyroid cancer diagnostic device that measures tissue compressibility to better distinguish between benign and malignant nodules. The 18-month trial at Bern University Hospital targets patients with Bethesda IV nodules to help reduce unnecessary thyroid surgeries.
• July 2025: Fred Hutch Cancer Center launched the Vanguard Study, the first trial under the Cancer Screening Research Network (CSRN), to assess the effectiveness of multi-cancer detection (MCD) blood tests in adults aged 45-75.


Considered in this report
• Historic Year: 2020
• Base year: 2025
• Estimated year: 2026
• Forecast year: 2031

Aspects covered in this report
• Cancer Diagnostics Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Product Type
• Consumables and reagents
• Instruments

By Technology
• IVD testing
• Anatomic pathology
• Diagnostic imaging
• Biopsy

By Application
• Breast Cancer
• Colorectal Cancer
• Lung Cancer
• Prostate Cancer
• Others

***Please Note: It will take 48 hours (2 Business days) for delivery of the report upon order confirmation.



ページTOPに戻る


Table of Contents

Table of Content

1. Executive Summary
2. Market Dynamics
2.1. Market Drivers & Opportunities
2.2. Market Restraints & Challenges
2.3. Market Trends
2.4. Supply chain Analysis
2.5. Policy & Regulatory Framework
2.6. Industry Experts Views
3. Research Methodology
3.1. Secondary Research
3.2. Primary Data Collection
3.3. Market Formation & Validation
3.4. Report Writing, Quality Check & Delivery
4. Market Structure
4.1. Market Considerate
4.2. Assumptions
4.3. Limitations
4.4. Abbreviations
4.5. Sources
4.6. Definitions
5. Economic /Demographic Snapshot
6. Global Cancer Diagnostics Market Outlook
6.1. Market Size By Value
6.2. Market Share By Region
6.3. Market Size and Forecast, By Geography
6.4. Market Size and Forecast, By Product Type
6.4.1. Market Size and Forecast, By Consumables and reagents
6.4.2. Market Size and Forecast, By Instruments
6.5. Market Size and Forecast, By Technology
6.6. Market Size and Forecast, By Application
6.7. Market Size and Forecast, By End User
7. North America Cancer Diagnostics Market Outlook
7.1. Market Size By Value
7.2. Market Share By Country
7.3. Market Size and Forecast, By Product Type
7.4. Market Size and Forecast, By Technology
7.5. Market Size and Forecast, By Application
7.6. Market Size and Forecast, By End User
7.7. United States Cancer Diagnostics Market Outlook
7.7.1. Market Size by Value
7.7.2. Market Size and Forecast By Product Type
7.7.3. Market Size and Forecast By Technology
7.7.4. Market Size and Forecast By Application
7.8. Canada Cancer Diagnostics Market Outlook
7.8.1. Market Size by Value
7.8.2. Market Size and Forecast By Product Type
7.8.3. Market Size and Forecast By Technology
7.8.4. Market Size and Forecast By Application
7.9. Mexico Cancer Diagnostics Market Outlook
7.9.1. Market Size by Value
7.9.2. Market Size and Forecast By Product Type
7.9.3. Market Size and Forecast By Technology
7.9.4. Market Size and Forecast By Application
8. Europe Cancer Diagnostics Market Outlook
8.1. Market Size By Value
8.2. Market Share By Country
8.3. Market Size and Forecast, By Product Type
8.4. Market Size and Forecast, By Technology
8.5. Market Size and Forecast, By Application
8.6. Market Size and Forecast, By End User
8.7. Germany Cancer Diagnostics Market Outlook
8.7.1. Market Size by Value
8.7.2. Market Size and Forecast By Product Type
8.7.3. Market Size and Forecast By Technology
8.7.4. Market Size and Forecast By Application
8.8. United Kingdom (UK) Cancer Diagnostics Market Outlook
8.8.1. Market Size by Value
8.8.2. Market Size and Forecast By Product Type
8.8.3. Market Size and Forecast By Technology
8.8.4. Market Size and Forecast By Application
8.9. France Cancer Diagnostics Market Outlook
8.9.1. Market Size by Value
8.9.2. Market Size and Forecast By Product Type
8.9.3. Market Size and Forecast By Technology
8.9.4. Market Size and Forecast By Application
8.10. Italy Cancer Diagnostics Market Outlook
8.10.1. Market Size by Value
8.10.2. Market Size and Forecast By Product Type
8.10.3. Market Size and Forecast By Technology
8.10.4. Market Size and Forecast By Application
8.11. Spain Cancer Diagnostics Market Outlook
8.11.1. Market Size by Value
8.11.2. Market Size and Forecast By Product Type
8.11.3. Market Size and Forecast By Technology
8.11.4. Market Size and Forecast By Application
8.12. Russia Cancer Diagnostics Market Outlook
8.12.1. Market Size by Value
8.12.2. Market Size and Forecast By Product Type
8.12.3. Market Size and Forecast By Technology
8.12.4. Market Size and Forecast By Application
9. Asia-Pacific Cancer Diagnostics Market Outlook
9.1. Market Size By Value
9.2. Market Share By Country
9.3. Market Size and Forecast, By Product Type
9.4. Market Size and Forecast, By Technology
9.5. Market Size and Forecast, By Application
9.6. Market Size and Forecast, By End User
9.7. China Cancer Diagnostics Market Outlook
9.7.1. Market Size by Value
9.7.2. Market Size and Forecast By Product Type
9.7.3. Market Size and Forecast By Technology
9.7.4. Market Size and Forecast By Application
9.8. Japan Cancer Diagnostics Market Outlook
9.8.1. Market Size by Value
9.8.2. Market Size and Forecast By Product Type
9.8.3. Market Size and Forecast By Technology
9.8.4. Market Size and Forecast By Application
9.9. India Cancer Diagnostics Market Outlook
9.9.1. Market Size by Value
9.9.2. Market Size and Forecast By Product Type
9.9.3. Market Size and Forecast By Technology
9.9.4. Market Size and Forecast By Application
9.10. Australia Cancer Diagnostics Market Outlook
9.10.1. Market Size by Value
9.10.2. Market Size and Forecast By Product Type
9.10.3. Market Size and Forecast By Technology
9.10.4. Market Size and Forecast By Application
9.11. South Korea Cancer Diagnostics Market Outlook
9.11.1. Market Size by Value
9.11.2. Market Size and Forecast By Product Type
9.11.3. Market Size and Forecast By Technology
9.11.4. Market Size and Forecast By Application
10. South America Cancer Diagnostics Market Outlook
10.1. Market Size By Value
10.2. Market Share By Country
10.3. Market Size and Forecast, By Product Type
10.4. Market Size and Forecast, By Technology
10.5. Market Size and Forecast, By Application
10.6. Market Size and Forecast, By End User
10.7. Brazil Cancer Diagnostics Market Outlook
10.7.1. Market Size by Value
10.7.2. Market Size and Forecast By Product Type
10.7.3. Market Size and Forecast By Technology
10.7.4. Market Size and Forecast By Application
10.8. Argentina Cancer Diagnostics Market Outlook
10.8.1. Market Size by Value
10.8.2. Market Size and Forecast By Product Type
10.8.3. Market Size and Forecast By Technology
10.8.4. Market Size and Forecast By Application
10.9. Colombia Cancer Diagnostics Market Outlook
10.9.1. Market Size by Value
10.9.2. Market Size and Forecast By Product Type
10.9.3. Market Size and Forecast By Technology
10.9.4. Market Size and Forecast By Application
11. Middle East & Africa Cancer Diagnostics Market Outlook
11.1. Market Size By Value
11.2. Market Share By Country
11.3. Market Size and Forecast, By Product Type
11.4. Market Size and Forecast, By Technology
11.5. Market Size and Forecast, By Application
11.6. Market Size and Forecast, By End User
11.7. United Arab Emirates (UAE) Cancer Diagnostics Market Outlook
11.7.1. Market Size by Value
11.7.2. Market Size and Forecast By Product Type
11.7.3. Market Size and Forecast By Technology
11.7.4. Market Size and Forecast By Application
11.8. Saudi Arabia Cancer Diagnostics Market Outlook
11.8.1. Market Size by Value
11.8.2. Market Size and Forecast By Product Type
11.8.3. Market Size and Forecast By Technology
11.8.4. Market Size and Forecast By Application
11.9. South Africa Cancer Diagnostics Market Outlook
11.9.1. Market Size by Value
11.9.2. Market Size and Forecast By Product Type
11.9.3. Market Size and Forecast By Technology
11.9.4. Market Size and Forecast By Application
12. Competitive Landscape
12.1. Competitive Dashboard
12.2. Business Strategies Adopted by Key Players
12.3. Key Players Market Share Insights and Analysis, 2025
12.4. Key Players Market Positioning Matrix
12.5. Porter's Five Forces
12.6. Company Profile
12.6.1. Thermo Fisher Scientific Inc.
12.6.1.1. Company Snapshot
12.6.1.2. Company Overview
12.6.1.3. Financial Highlights
12.6.1.4. Geographic Insights
12.6.1.5. Business Segment & Performance
12.6.1.6. Product Portfolio
12.6.1.7. Key Executives
12.6.1.8. Strategic Moves & Developments
12.6.2. Abbott Laboratories
12.6.3. Agilent Technologies, Inc.
12.6.4. Roche Diagnostics
12.6.5. Danaher Corporation
12.6.6. Siemens Healthineers AG
12.6.7. QIAGEN N.V.
12.6.8. Becton, Dickinson and Company (BD)
12.6.9. Illumina, Inc.
12.6.10. Hologic, Inc.
12.6.11. bioMérieux SA
12.6.12. Foundation Medicine, Inc.
12.6.13. Sysmex Corporation
12.6.14. NeoGenomics Laboratories, Inc.
12.6.15. Myriad Genetics, Inc.
12.6.16. Exact Sciences Corporation
12.6.17. Guardant Health, Inc.
12.6.18. GRAIL, Inc.
12.6.19. Natera, Inc.
12.6.20. Tempus AI, Inc.
13. Strategic Recommendations
14. Annexure
14.1. FAQ`s
14.2. Notes
15. Disclaimer

ページTOPに戻る



List of Tables/Graphs

List of Figures

Figure 1: Global Cancer Diagnostics Market Size (USD Billion) By Region, 2025 & 2031F
Figure 2: Market attractiveness Index, By Region 2031F
Figure 3: Market attractiveness Index, By Segment 2031F
Figure 4: Global Cancer Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 5: Global Cancer Diagnostics Market Share By Region (2025)
Figure 6: North America Cancer Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 7: North America Cancer Diagnostics Market Share By Country (2025)
Figure 8: US Cancer Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 9: Canada Cancer Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 10: Mexico Cancer Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 11: Europe Cancer Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 12: Europe Cancer Diagnostics Market Share By Country (2025)
Figure 13: Germany Cancer Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 14: United Kingdom (UK) Cancer Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 15: France Cancer Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 16: Italy Cancer Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 17: Spain Cancer Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 18: Russia Cancer Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 19: Asia-Pacific Cancer Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 20: Asia-Pacific Cancer Diagnostics Market Share By Country (2025)
Figure 21: China Cancer Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 22: Japan Cancer Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 23: India Cancer Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 24: Australia Cancer Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 25: South Korea Cancer Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 26: South America Cancer Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 27: South America Cancer Diagnostics Market Share By Country (2025)
Figure 28: Brazil Cancer Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 29: Argentina Cancer Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 30: Colombia Cancer Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 31: Middle East & Africa Cancer Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 32: Middle East & Africa Cancer Diagnostics Market Share By Country (2025)
Figure 33: United Arab Emirates (UAE) Cancer Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 34: Saudi Arabia Cancer Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 35: South Africa Cancer Diagnostics Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 36: Porter's Five Forces of Global Cancer Diagnostics Market


List of Tables

Table 1: Global Cancer Diagnostics Market Snapshot, By Segmentation (2025 & 2031F) (in USD Billion)
Table 2: Influencing Factors for Cancer Diagnostics Market, 2025
Table 3: Top 10 Counties Economic Snapshot 2024
Table 4: Economic Snapshot of Other Prominent Countries 2022
Table 5: Average Exchange Rates for Converting Foreign Currencies into U.S. Dollars
Table 6: Global Cancer Diagnostics Market Size and Forecast, By Geography (2020 to 2031F) (In USD Billion)
Table 7: Global Cancer Diagnostics Market Size and Forecast, By Product Type (2020 to 2031F) (In USD Billion)
Table 8: Global Cancer Diagnostics Market Size and Forecast, By Consumables and reagents (2020 to 2031F) (In USD Billion)
Table 9: Global Cancer Diagnostics Market Size and Forecast, By Instruments (2020 to 2031F) (In USD Billion)
Table 10: Global Cancer Diagnostics Market Size and Forecast, By Technology (2020 to 2031F) (In USD Billion)
Table 11: Global Cancer Diagnostics Market Size and Forecast, By Application (2020 to 2031F) (In USD Billion)
Table 12: Global Cancer Diagnostics Market Size and Forecast, By End User (2020 to 2031F) (In USD Billion)
Table 13: North America Cancer Diagnostics Market Size and Forecast, By Product Type (2020 to 2031F) (In USD Billion)
Table 14: North America Cancer Diagnostics Market Size and Forecast, By Technology (2020 to 2031F) (In USD Billion)
Table 15: North America Cancer Diagnostics Market Size and Forecast, By Application (2020 to 2031F) (In USD Billion)
Table 16: North America Cancer Diagnostics Market Size and Forecast, By End User (2020 to 2031F) (In USD Billion)
Table 17: United States Cancer Diagnostics Market Size and Forecast By Product Type (2020 to 2031F) (In USD Billion)
Table 18: United States Cancer Diagnostics Market Size and Forecast By Technology (2020 to 2031F) (In USD Billion)
Table 19: United States Cancer Diagnostics Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)
Table 20: Canada Cancer Diagnostics Market Size and Forecast By Product Type (2020 to 2031F) (In USD Billion)
Table 21: Canada Cancer Diagnostics Market Size and Forecast By Technology (2020 to 2031F) (In USD Billion)
Table 22: Canada Cancer Diagnostics Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)
Table 23: Mexico Cancer Diagnostics Market Size and Forecast By Product Type (2020 to 2031F) (In USD Billion)
Table 24: Mexico Cancer Diagnostics Market Size and Forecast By Technology (2020 to 2031F) (In USD Billion)
Table 25: Mexico Cancer Diagnostics Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)
Table 26: Europe Cancer Diagnostics Market Size and Forecast, By Product Type (2020 to 2031F) (In USD Billion)
Table 27: Europe Cancer Diagnostics Market Size and Forecast, By Technology (2020 to 2031F) (In USD Billion)
Table 28: Europe Cancer Diagnostics Market Size and Forecast, By Application (2020 to 2031F) (In USD Billion)
Table 29: Europe Cancer Diagnostics Market Size and Forecast, By End User (2020 to 2031F) (In USD Billion)
Table 30: Germany Cancer Diagnostics Market Size and Forecast By Product Type (2020 to 2031F) (In USD Billion)
Table 31: Germany Cancer Diagnostics Market Size and Forecast By Technology (2020 to 2031F) (In USD Billion)
Table 32: Germany Cancer Diagnostics Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)
Table 33: United Kingdom (UK) Cancer Diagnostics Market Size and Forecast By Product Type (2020 to 2031F) (In USD Billion)
Table 34: United Kingdom (UK) Cancer Diagnostics Market Size and Forecast By Technology (2020 to 2031F) (In USD Billion)
Table 35: United Kingdom (UK) Cancer Diagnostics Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)
Table 36: France Cancer Diagnostics Market Size and Forecast By Product Type (2020 to 2031F) (In USD Billion)
Table 37: France Cancer Diagnostics Market Size and Forecast By Technology (2020 to 2031F) (In USD Billion)
Table 38: France Cancer Diagnostics Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)
Table 39: Italy Cancer Diagnostics Market Size and Forecast By Product Type (2020 to 2031F) (In USD Billion)
Table 40: Italy Cancer Diagnostics Market Size and Forecast By Technology (2020 to 2031F) (In USD Billion)
Table 41: Italy Cancer Diagnostics Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)
Table 42: Spain Cancer Diagnostics Market Size and Forecast By Product Type (2020 to 2031F) (In USD Billion)
Table 43: Spain Cancer Diagnostics Market Size and Forecast By Technology (2020 to 2031F) (In USD Billion)
Table 44: Spain Cancer Diagnostics Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)
Table 45: Russia Cancer Diagnostics Market Size and Forecast By Product Type (2020 to 2031F) (In USD Billion)
Table 46: Russia Cancer Diagnostics Market Size and Forecast By Technology (2020 to 2031F) (In USD Billion)
Table 47: Russia Cancer Diagnostics Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)
Table 48: Asia-Pacific Cancer Diagnostics Market Size and Forecast, By Product Type (2020 to 2031F) (In USD Billion)
Table 49: Asia-Pacific Cancer Diagnostics Market Size and Forecast, By Technology (2020 to 2031F) (In USD Billion)
Table 50: Asia-Pacific Cancer Diagnostics Market Size and Forecast, By Application (2020 to 2031F) (In USD Billion)
Table 51: Asia-Pacific Cancer Diagnostics Market Size and Forecast, By End User (2020 to 2031F) (In USD Billion)
Table 52: China Cancer Diagnostics Market Size and Forecast By Product Type (2020 to 2031F) (In USD Billion)
Table 53: China Cancer Diagnostics Market Size and Forecast By Technology (2020 to 2031F) (In USD Billion)
Table 54: China Cancer Diagnostics Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)
Table 55: Japan Cancer Diagnostics Market Size and Forecast By Product Type (2020 to 2031F) (In USD Billion)
Table 56: Japan Cancer Diagnostics Market Size and Forecast By Technology (2020 to 2031F) (In USD Billion)
Table 57: Japan Cancer Diagnostics Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)
Table 58: India Cancer Diagnostics Market Size and Forecast By Product Type (2020 to 2031F) (In USD Billion)
Table 59: India Cancer Diagnostics Market Size and Forecast By Technology (2020 to 2031F) (In USD Billion)
Table 60: India Cancer Diagnostics Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)
Table 61: Australia Cancer Diagnostics Market Size and Forecast By Product Type (2020 to 2031F) (In USD Billion)
Table 62: Australia Cancer Diagnostics Market Size and Forecast By Technology (2020 to 2031F) (In USD Billion)
Table 63: Australia Cancer Diagnostics Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)
Table 64: South Korea Cancer Diagnostics Market Size and Forecast By Product Type (2020 to 2031F) (In USD Billion)
Table 65: South Korea Cancer Diagnostics Market Size and Forecast By Technology (2020 to 2031F) (In USD Billion)
Table 66: South Korea Cancer Diagnostics Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)
Table 67: South America Cancer Diagnostics Market Size and Forecast, By Product Type (2020 to 2031F) (In USD Billion)
Table 68: South America Cancer Diagnostics Market Size and Forecast, By Technology (2020 to 2031F) (In USD Billion)
Table 69: South America Cancer Diagnostics Market Size and Forecast, By Application (2020 to 2031F) (In USD Billion)
Table 70: South America Cancer Diagnostics Market Size and Forecast, By End User (2020 to 2031F) (In USD Billion)
Table 71: Brazil Cancer Diagnostics Market Size and Forecast By Product Type (2020 to 2031F) (In USD Billion)
Table 72: Brazil Cancer Diagnostics Market Size and Forecast By Technology (2020 to 2031F) (In USD Billion)
Table 73: Brazil Cancer Diagnostics Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)
Table 74: Argentina Cancer Diagnostics Market Size and Forecast By Product Type (2020 to 2031F) (In USD Billion)
Table 75: Argentina Cancer Diagnostics Market Size and Forecast By Technology (2020 to 2031F) (In USD Billion)
Table 76: Argentina Cancer Diagnostics Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)
Table 77: Colombia Cancer Diagnostics Market Size and Forecast By Product Type (2020 to 2031F) (In USD Billion)
Table 78: Colombia Cancer Diagnostics Market Size and Forecast By Technology (2020 to 2031F) (In USD Billion)
Table 79: Colombia Cancer Diagnostics Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)
Table 80: Middle East & Africa Cancer Diagnostics Market Size and Forecast, By Product Type (2020 to 2031F) (In USD Billion)
Table 81: Middle East & Africa Cancer Diagnostics Market Size and Forecast, By Technology (2020 to 2031F) (In USD Billion)
Table 82: Middle East & Africa Cancer Diagnostics Market Size and Forecast, By Application (2020 to 2031F) (In USD Billion)
Table 83: Middle East & Africa Cancer Diagnostics Market Size and Forecast, By End User (2020 to 2031F) (In USD Billion)
Table 84: United Arab Emirates (UAE) Cancer Diagnostics Market Size and Forecast By Product Type (2020 to 2031F) (In USD Billion)
Table 85: United Arab Emirates (UAE) Cancer Diagnostics Market Size and Forecast By Technology (2020 to 2031F) (In USD Billion)
Table 86: United Arab Emirates (UAE) Cancer Diagnostics Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)
Table 87: Saudi Arabia Cancer Diagnostics Market Size and Forecast By Product Type (2020 to 2031F) (In USD Billion)
Table 88: Saudi Arabia Cancer Diagnostics Market Size and Forecast By Technology (2020 to 2031F) (In USD Billion)
Table 89: Saudi Arabia Cancer Diagnostics Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)
Table 90: South Africa Cancer Diagnostics Market Size and Forecast By Product Type (2020 to 2031F) (In USD Billion)
Table 91: South Africa Cancer Diagnostics Market Size and Forecast By Technology (2020 to 2031F) (In USD Billion)
Table 92: South Africa Cancer Diagnostics Market Size and Forecast By Application (2020 to 2031F) (In USD Billion)
Table 93: Competitive Dashboard of top 5 players, 2025
Table 94: Key Players Market Share Insights and Analysis for Cancer Diagnostics Market 2025

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同じKEY WORD()の最新刊レポート

  • 本レポートと同じKEY WORDの最新刊レポートはありません。

よくあるご質問


Bonafide Research & Marketing Pvt. Ltd.社はどのような調査会社ですか?


Bonafide Research & Marketing Pvt. Ltd.は、最新の経済、人口統計、貿易、市場データを提供する市場調査・コンサルティング会社です。調査レポート、カスタムレポート、コ... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。


詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

 

2026/11/17 10:26

160.48 円

176.90 円

214.31 円

ページTOPに戻る